Cargando…

Drug metabolism and pancreatic cancer

Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient’s individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more e...

Descripción completa

Detalles Bibliográficos
Autores principales: Flores, John Paul E., Diasio, Robert B., Saif, Muhammad Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198247/
https://www.ncbi.nlm.nih.gov/pubmed/28042238
http://dx.doi.org/10.20524/aog.2016.0074
_version_ 1782488856407310336
author Flores, John Paul E.
Diasio, Robert B.
Saif, Muhammad Wasif
author_facet Flores, John Paul E.
Diasio, Robert B.
Saif, Muhammad Wasif
author_sort Flores, John Paul E.
collection PubMed
description Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient’s individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality.
format Online
Article
Text
id pubmed-5198247
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-51982472017-01-01 Drug metabolism and pancreatic cancer Flores, John Paul E. Diasio, Robert B. Saif, Muhammad Wasif Ann Gastroenterol Review Article Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient’s individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality. Hellenic Society of Gastroenterology 2017 2016-07-21 /pmc/articles/PMC5198247/ /pubmed/28042238 http://dx.doi.org/10.20524/aog.2016.0074 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Flores, John Paul E.
Diasio, Robert B.
Saif, Muhammad Wasif
Drug metabolism and pancreatic cancer
title Drug metabolism and pancreatic cancer
title_full Drug metabolism and pancreatic cancer
title_fullStr Drug metabolism and pancreatic cancer
title_full_unstemmed Drug metabolism and pancreatic cancer
title_short Drug metabolism and pancreatic cancer
title_sort drug metabolism and pancreatic cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198247/
https://www.ncbi.nlm.nih.gov/pubmed/28042238
http://dx.doi.org/10.20524/aog.2016.0074
work_keys_str_mv AT floresjohnpaule drugmetabolismandpancreaticcancer
AT diasiorobertb drugmetabolismandpancreaticcancer
AT saifmuhammadwasif drugmetabolismandpancreaticcancer